Prospects for the treatment of type 1 diabetes: the possibility of recovery
Type 1 diabetes is an autoimmune disease that leads to the destruction of the pancreatic cells that produce insulin. Amanda Smith from the UN was diagnosed with the disease in 2015 when she noticed blurred vision caused by high blood sugar. After being hospitalized, she was diagnosed with type 1 diabetes. For years, Amanda suffered from constant fluctuations in her sugar levels, putting a strain on herself and her family. However, in the past few months, she has been part of a trial of a new drug, VX-880, which could lead to the elimination of the need for additional insulin.
Source National Geographic
This drug, developed by Vertex Pharmaceuticals, is undergoing clinical trials to assess changes in patients' condition. Currently, the prospects of VX-880 are being assessed, which can be administered to about 40-60 thousand patients in the US and Europe. The essence of the new therapy is the efficiency of insulin-secreting cells; experts note that this approach can significantly change diabetes trials, simplifying the lives of patients and potentially laying the foundation for the treatment of other diseases.
Doctors note that although this therapy involves immunosuppressive drugs, it opens a new era in diabetes treatment. According to the researchers, the right direction is not only to improve the condition of patients, but also to restore beta-cell function, eliminating the underlying problem. If the clinical trials are successful, it will have a significant impact on the treatment of type 1 diabetes and other autoimmune diseases.
